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Abstract
Transport mechanisms, whereby alimentary lipids are digested and packaged into small emulsion
particles that enter intestinal cells to be translocated to the plasma in the form of chylomicrons,
are impaired in cystic fibrosis. The purpose of this paper is to focus on defects that are related to
intraluminal and intracellular events in this life-limiting genetic disorder. Specific evidence is
presented to highlight the relationship between fat malabsorption and essential fatty acid deficiency
commonly found in patients with cystic fibrosis that are often related to the genotype. Given the
interdependency of pulmonary disease, pancreatic insufficiency and nutritional status, greater
attention should be paid to the optimal correction of fat malabsorption and essential fatty acid
deficiency in order to improve the quality of life and extend the life span of patients with cystic
fibrosis.
I Introduction
Cystic fibrosis (CF) is the most common autosomal reces-
sive genetic disease observed in the Caucasian population,
affecting about 1 in 2,500 newborns. It is caused by muta-
tions in the Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR) gene discovered in 1989. The gene was
cloned from chromosome 7q21-31, is composed of 27
exons and encodes a protein that functions as a chloride
channel [1-4]. CFTR has 1,480 amino acids and the
molecular weight varies from 140 kDA to 170 kDA,
depending upon the degree of posttranslational glycation
in the Golgi complex, which appears to vary somewhat
according to cell type and genotype. Defective cAMP-
dependent chloride ion conductance leads to an imbal-
ance in fluid flow across epithelia, thickened mucus and
blocked exocrine ducts in the affected tissues. In addition
to respiratory-tract manifestations that represent the
major cause of death in CF, the vast majority of young CF
subjects have a wide variability of clinical expression,
including gastrointestinal, metabolic and nutritional
problems [5,6]. Advances in medical management have
led to a continual improvement of life expectancy for CF
patients. However, intestinal fat malabsorption remains a
persistent feature, given the difficulty of achieving com-
plete correction in clinical practice despite the remarkable
benefits resulting from exogenous pancreatic enzyme
replacement therapy. [7-11]. The purpose of this article is
to present a systematic critical review of literature and data
sources pertaining to fat malabsorption in CF, emphasiz-
ing the role of abnormal, intraluminal and intracellular
factors. Furthermore, the relationship between essential
fatty acid deficiency (EFAD) and intestinal fat transport is
particularly underscored given its implication in gastroin-
testinal pathophysiology. To facilitate the reader's appre-
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first describe the normal digestive and absorptive proc-
esses before addressing the issue of various defective
mechanisms in CF.
II Lipids and Essential Fatty Acids (EFAs)
Dietary fat intake represents 35% (100 to 150 g per day)
of total calories consumed in the North American diet
[12]. Dietary fats are composed mainly of triacylglycerol
(TG) with 92–96% long-chain fatty acids [13]. In addition
to dietary intake, lipids are derived from bile and desqua-
mated mucosal cells.
Lipids have varied as well as essential functions in organ-
isms. TGs are the principal reserve supply of energy, while
phospholipids (PLs) and cholesterol are crucial for the
elaboration of cell membranes, and play a functional role
in steroid hormone and biliary acid (BA) synthesis. Lino-
leic (18:2n-6) and linolenic (18:3n-3) acids have recog-
nized functions in growth, the development of the central
nervous system, immune and vascular functions, eicosa-
noid production, membrane fluidity and the control of
lipid homeostasis. Adequate EFA levels depend entirely
on adequate dietary intake and absorption because mam-
malian cells cannot synthesize de novo EFA efficiently.
Once these EFAs are appropriately absorbed, they can be
converted into long-chain polyunsaturated fatty acids
(PUFAs) such as arachidonic acid (AA, 20:4n-6), eicosap-
entaenoic (EPA, 20:5n-3) and docosahexaenoic acid
(DHA, 22:6n-3). Conditions leading to fat malabsorp-
tion, as in CF, have been associated with a high incidence
of EFAD. However, diet-induced EFAD impairs dietary
lipid absorption through various mechanisms, which will
be thoroughly discussed sin this review.
II.1. CF Patients and EFAD
A high EFAD incidence (85%) has been frequently
reported in CF patients [14-19]. EFAD is most marked at
infancy [20] and EFA impairment has been observed most
significantly in the cholesteryl ester (CE) fraction [15,21].
The most often reported abnormalities in plasma are a
decrease in linoleic acid and AA, its major metabolites, as
well as DHA [22]. This EFA diminution is associated with
an elevation in eicosatrienoic acid (20:3n-9), oleic acid
(18:1n-9) and palmitoleic acid (16:1n-7) [14,23,24],
resulting in a rise in the triene/tetraene ratio. It has been
suggested that the (20:3n-9/20:4n-6) ratio is a very sensi-
tive and reliable index of EFAD. A value of the ratio above
0.2 indicates an appropriate cutoff for the diagnosis of
EFAD [25]. However, results obtained from CF studies
vary, possibly as a consequence of different nutritional
status, the degree of malabsorption and the severity of the
CFTR mutation.
Abnormal EFA status in CF patients does not seem to be
the consequence of intestinal malabsorption only, since
reduced EFA values are found as early as in the first weeks
of life in infants with CF [22] and they are also present in
well-nourished young CF patients who do not receive a
low-fat diet and do not present with fat malabsorption
[17,24,26-28] even with regular pancreatic enzyme ther-
apy [21]. Among other mechanisms related to EFAD, one
can mention the excessive oxidation of EFA as an energy
source [29], the exaggerated utilization of eicosanoids as
precursors of inflammatory response [30,31], the higher
rate of lipid turnover in cell membranes [32], the
impaired metabolism of EFA with a defect in plasma
membrane incorporation, the decreased activity of desat-
urases [14,33] and lipid peroxidation [34].
II.2. Relationship between CFTR and EFAD
CFTR primarily functions as a chloride channel in the api-
cal membrane of the respiratory and gastro-intestinal
tracts. An elevation of cAMP within the cell results in
increased chloride transport through the CFTR. Move-
ment of water is linked osmotically to such ion transport
and chloride secretion represents one likely means of
hydrating the mucosal surface of these organs. Other
important studies have implicated the CFTR in additional
functions, including the regulation of distinct Cl- channel
proteins, the modulation of intracellular vesicle and Golgi
acidification, and the control of vesicle trafficking [35-40].
Furthermore, it has been suggested that the CFTR may reg-
ulate membrane PL composition. In human airway epi-
thelial cultured cells, the incorporation of fatty acids (FAs)
into membrane PLs is decreased when chloride conduct-
ance channels are chemically blocked [41]. A defective
CFTR reduces the incorporation of linoleic acid in the PL
of CF cells and transfecting these cells with the normal
gene increases linoleic acid incorporation [42]. Thus, a
relationship is possible between chloride transport con-
ductance and EFA metabolism. To date, these studies are
limited and additional investigation is needed to establish
the role of the chloride channel function in EFA move-
ment and metabolism.
CFTR knock-out mice demonstrate EFAD. But the EFA
composition of the cell membrane varies with different
animal models. In cftr-/- mouse, the pancreas, lungs and
ileum were deficient in (n-3) EFA [43], whereas in cftr
tm1HGU/tm1HGU mice, the deficiency was in (n-6) EFA in
plasma, lung and pancreatic PL [44]. The PUFA differ-
ences between the two mouse models emphasize the
importance of determining the exact composition of
membrane PL from healthy men and CF patients accord-
ing to genotype in order to tailor appropriate EFA nutri-
tional intervention.Page 2 of 18
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result from an impaired EFA metabolism. High levels of
AA are also reported in the cell membrane of the ileum of
CFTR knock-out mice [43]. The same AA imbalance has
been reported in the PL fraction deriving from bronchial
alveolar lavage fluid, plasma and tissues [31,45-48] of CF
patients. The increased AA level in tissues may result from
either overproduction or diminished catabolism. In CF
cells (CFPAC-1), the conversion of 18:2n-6 into 20:4n-6
by desaturation and elongation processes is enhanced 1.8-
fold compared with CF cells transfected with the normal
gene [42]. AA overproduction is compatible with an
intrinsic increase in AA release by CFTR-mutated respira-
tory epithelial cell lines [49]. A decreased metabolism of
AA through cyclooxygenase, lipooxygenase or cytochrome
P450 pathways could also explain high levels of AA in tis-
sues, but this hypothesis should be thoroughly tested in
CF because of a) the high rates of inflammatory species
originating from AA that characterize CF patients; and b)
the enhanced turnover of endogenous and exogenous AA
in polymorph neutrophil granulocytes, which is possibly
due to enhanced phospholipase A2 (PLA2) activity [50].
Then, AA catabolism is not obviously diminished, but the
ratio between production and degradation may be unbal-
anced in favor of overproduction. Accordingly, it has been
suggested that AA participates in CF physiopathology,
since AA has been shown to inhibit CFTR Cl- currents
when applied to the cytoplasmic face of excised mem-
brane patches [51,52]. Other FAs may also block CFTR
pores with various levels of efficiency. For example, cis-
unsaturated FAs are more effective than trans-unsaturated
FAs and saturated FAs in interfering with CFTR function
[52]. Furthermore, in respiratory epithelial cells, CFTR
mutation ∆F508 is associated with an intrinsic increase in
AA release [49] suggesting that the mechanism of chronic
inflammation in CF, at least in part, involves this abnor-
mality. Importantly, Chlore ion (Cl-) secretion across epi-
thelial cells is induced by AA [53,54]. On the other hand,
AA decreases Cl- secretion across tracheal epithelium
when its metabolism is impaired by cyclooxygenase and
lipooxygenase inhibitors [54] suggesting that enhanced
Cl- secretion results from the action of its metabolites [52].
Furthermore, there is a correlation between EFAD and CF
genotype in homozygotes for ∆F508 and heterozygotes
for 394 delTT have displayed significantly lower concen-
trations of linoleic and DHA than the other mutations
[55]. Thus, the relationship between AA metabolism
abnormalities and specific mutations may explain the dis-
crepancies observed with n-6 EFA supplementation
[19,22,56-58]. Evidently, extensive studies are required to
clarify the link between the CFTR and FAs, especially in
view of the contribution of EFAD to CF pathophysiology.
In animals, EFAD induces symptoms similar to those in
CF: defective Na+ transport, increased bacterial coloniza-
tion of airways, formation of clusters of lipid-laden mac-
rophages in lungs [59], impaired alveolar macrophage
function [60], alteration of surfactants [61], liver steatosis,
decreased insulin secretion and increased caloric needs
[62]. Interestingly, a membrane lipid imbalance plays a
role in the phenotype expression in CFTR knock-out mice
and feeding these animals with DHA has normalized dis-
ease-related changes that occur in epithelial cells and
intestinal mucosa [63].
Of note is the finding that altered PL composition and
structure can impair membrane fluidity [64-66], thereby
modifying CFTR cell membrane localization and func-
tion. Membrane PL composition in CFTR knock-out mice
is different from controls [44]. Apparently, lipid mem-
brane composition regulates membrane protein activity
through the association between lipid rafts and these pro-
teins [67]. The transient residency of proteins in rafts
emerges as a regulatory mechanism responsible for pro-
tein biological activity. Recently, it has been reported that
lipid raft localization for CFTR is required for signaling in
response to Pseudomonas aeruginosa infection, underly-
ing the interaction between the lipid composition of
plasma membrane and the CFTR protein [68]. It seems,
therefore, that a correction of PL composition may
improve CFTR activity in vivo, a hypothesis that calls for
direct experimental validation in intestinal cells.
II.3. Nutritional Status and Prognosis in CF
Various studies emphasize a correlation between a low
nutritional status and an unfavorable prognosis in
patients with CF [69]. Chronic undernutrition is associ-
ated with weight and height retardation in CF children.
Early studies showed a correlation between the degree of
malnutrition and the severity of pulmonary disease [69-
71] and a slower rate of deterioration of pulmonary func-
tion was found in CF children without steatorrhea [72].
However, low values of EFA (linoleic acid and DHA) are
not always correlated with anthropometric data or lung
function [55]. CF survival and well-being are also corre-
lated with malnutrition in CF [73]. This positive correla-
tion between good nutritional status and long-term
survival underscores the optimization of energy balance,
nutrient intake, as well as intestinal absorption for CF
patients.
Since EFA levels are abnormal in CF patients and EFAD
may contribute to CF pathophysiology in animal models,
it has been suggested that EFA supplementation has a ben-
eficial effect in this disease. Nutritional studies demon-
strate that oral and intravenous supplementations with n-
3 FAs are efficient in increasing EPA and DHA incorpora-
tion in plasma, erythrocyte and platelet membrane. [56-
58]. Oral supplementation with n-6 FAs increases plasma
and erythrocyte membrane AA levels [22,74-76]. The clin-Page 3 of 18
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linoleic acid increases weight for height in CF children
[19,22] and an improvement in pulmonary function is
also observed with n-3 FA intake. Nevertheless, this valu-
able effect is not reported in all studies. [56-58] and the
differences may be explained by the limited number of
patients (under 20) and the short duration (between 4
and 6 weeks) that prevent the proper evaluation of any
clinical benefit. Undoubtedly, further studies should
focus on the relationship between dose recommenda-
tions, the degree of correction of plasma EFAs and clinical
outcome. In particular, long-term lipid dosage adjust-
ments are necessary to define the optimal n-3/n-6 ratio
required in CF patients to prevent clinical manifestations.
In contrast to carbohydrates and proteins, lipids are
poorly soluble in water. Their lipolysis into the aqueous
phase of the intestinal lumen, as well as their transport
into plasma, requires the formation of soluble complexes
such as BAs and lipoproteins (LPs). Any deficiency or var-
iation in these processes may impact on fat digestion and
transport. Fat malabsorption in CF may result from the
inefficiency of sequential events: the lipolysis of alimen-
tary lipids, the effect of BAs on micellar solubilization, the
integrity of intestinal mucus and enterocytes, multiple
intracellular processes and LP secretion. These lipid diges-
tive and absorptive steps will be discussed chronologi-
cally.
III. Intraluminal Abnormalities
III.1.1. Lipolytic Phase
TGs cannot be transported into the cell because of their
size and their hydrophobic characteristics. The lipolysis
process is required to produce smaller and more
hydrophilic molecules, which can thus be absorbed. TGs
can be hydrolyzed by two lipolytic enzymes in humans:
gastric lipase and pancreatic lipase [77,78]. The enzyme
postulated to be the main participant in gastrointestinal
lipid digestion is pancreatic lipase. However, intra-gastric
lipolysis accounts for about 20–30% of total gastrointesti-
nal lipolysis in vivo and it has been suggested that it is
increased in CF pancreatic insufficiency.
III.1.1 Gastric Lipase
Human gastric lipase is the key acid enzyme that is
secreted by the chief cells located in the fundic region of
the stomach. Human gastric lipase is stable in gastric juice
at pH values ranging from 2.0 to 7.0 and is the most stable
acid lipase [79].
In the past, it was suggested that gastric lipase played only
a minor role in the digestion of dietary fat, because of its
specificity for medium-chain FAs, which are less common
than long-chain FAs in dietary fat [80]. In fact, human gas-
tric lipase also exerts an important activity on long-chain
TGs in an acidic pH. When pH levels are between 5 and 6,
it hydrolyzes medium-chain TGs more efficiently than
longer ones [81]. This lipase is quantitatively important,
contributing 20–30% of TG acyl chain hydrolysis [82-84].
Moreover, initial digestion of dietary fat in the stomach
was found to be an essential step for optimal intestinal
lipolysis for three reasons: releasing long-chain PUFA in
the stomach induces cholecystokinine output, which
stimulates pancreatic lipase secretion [85]; the efficiency
of pancreatic lipase is increased with partially hydrolyzed
TGs [86]; and free fatty acids (FFAs) enhance lipase bind-
ing to colipase [85].
Acid lipase activity exists in CF children [87,88], but its
level, compared with normal controls, varies among stud-
ies [89,90]. Basal lipase activity in the stomach and in the
duodenum is similar in CF patients and normal controls
[91], but its lipolytic activity is almost three times higher
in CF patients after a test meal [90]. There are two main
explanations for the maintained high activity of acid
lipase in CF patients. First, contrary to pancreatic lipase,
the low postprandial pH in the upper small intestine, due
to bicarbonate deficiency, does not inactivate gastric
lipase activity [92,93] and the latter is preserved for a
longer period than in normal subjects. Second, the inacti-
vation of gastric lipase is less effective, because of the low
concentration of BAs and pancreatic proteolytic enzymes
[94,95]. Compensatory lipolytic activity by gastric lipase
may account for 40–70% of dietary fat digestion [87,96].
In CF patients, preduodenal activity amounts to 90% of
the total lipase activity at the ligament of Treitz in the
postprandial state [96]. However, acid-resistant enzyme
supplements, such as fungal lipase, fail to prove efficacy in
CF [97]. No correlation between gastric lipase and EFA
status is reported in the literature.
III.1.2. Pancreatic Lipase and Colipase
Amphipathic molecules, monoacylglycerols (MG) and
FA, produced during TG hydrolysis, stabilize dietary fat
emulsion. Most of the fat digestion occurs in the upper
small intestine following the action of pancreatic lipase
and BAs. The hydrolysis of long-chain TGs is achieved by
pancreatic lipase. Its optimum pH is 8 and the enzyme
becomes inactive at a pH under 6 and is irreversibly inac-
tivated at a pH less than 4.5. Colipase is required for pan-
creatic lipase stabilization on lipid droplets and for
optimal lipolytic activity. At least, two other hydrolytic
enzymes are needed to release FAs: PLA2 and cholesterol
esterase (CET).
Fat malabsorption is present only when pancreatic
enzyme secretion is under 10% of normal [98]. On diag-
nosis, only 15% of CF patients have sufficient pancreatic
function for normal fat digestion [72]. The pancreatic
function decreases with time, since 37% of CF newbornsPage 4 of 18
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[99] and more than 90% of CF infants and younger chil-
dren display pancreatic insufficiency. The physiopathol-
ogy of pancreatic insufficiency results from several
abnormalities. In fact, pancreatic changes are caused by
the obstruction of small ducts by thick, sticky secretions
and cellular debris. A primary defect of fluid secretion
(water and bicarbonate) leads to high protein concentra-
tion in pancreatic juice [100]. Then, protein precipitation
blocks small pancreatic ducts and promotes pancreatic
acinar atrophy and fibrosis. The ratio of acinar cells to
connective tissue decreases progressively in the pancreas
of CF children until the normal structure of the pancreas
is lost. The role of the CFTR for normal proliferation and
differentiation of secretory cell populations has been
demonstrated in the lung and intestine of transgenic mice
[101,102] and, interestingly, the CFTR appears as a valua-
ble marker of human pancreatic duct cell development
and differentiation [103]. CFTR mutation may, therefore,
affect the proliferation of pancreatic secretory cells,
thereby favoring pancreatic insufficiency and physiopa-
thology.
Not only quantitative but also qualitative abnormalities
characterize pancreatic lipase activity. Pancreatic lipase
supplements are inactivated by acidic pH levels in the
small bowel: only 8% of active enzyme reaches the liga-
ment of Treitz [92,93]. The severity of pancreatic involve-
ment appears to increase with age and, even with
maximum pancreatic enzyme replacement therapy, a sub-
stantial proportion of ingested energy is probably malab-
sorbed.
There is little information about colipase in CF. Although,
colipase has been reported to be deficient in this disease
[104], its secretion is extremely variable in CF patients
[105]. More investigations are necessary to clarify this
aspect.
End products of gastric lipases are mainly one FFA and
one 1-3-diacylglycerol, while the lipolytic products of
pancreatic lipase are two FFAs (Sn-1 and Sn-3 postions)
and one 2-monoacylglycerol [106]. Furthermore, in con-
trast to pancreatic lipase, gastric lipase has been shown to
cleave not only the external ester bonds (n-1 and n-3 posi-
tion), but also the ester bond in the Sn-2 position [107].
This difference is important for nutritional intervention
with enteral defined structured TGs, which provide
medium-chain FA as a source of immediate energy. In
Caco-2 cell cultures, the addition of structured TGs con-
taining only octanoic acid, a non-EFA, in the Sn-1 and Sn-
3 position, but linoleic acid in the Sn-2 position in the
presence of gastric lipase, enhances the cellular uptake of
TGs, improves cellular EFAD and exhibits a beneficial
effect on lipid incorporation and LP production [108]. In
the rat, EFAs at the Sn-2 position appear faster in lymph
than EFAs at the terminal positions of TGs [109] and are
more readily recovered in lymph [110]. Defined TG with
EFA linoleic acid at the Sn-2 position increases the absorp-
tion of EFA in rats with fat malabsorption induced by bil-
iary and pancreatic diversion [111]. These results suggest
that structured TG, in the presence of gastric lipase, could
improve EFAD, despite the absence of pancreatic lipase
activity. In patients who are not supplemented with pan-
creatic enzymes, an organized lipid matrix containing lys-
ophosphatidylcholine (Lyso-PC), MG and FFA could be
effective in increasing TG and retinyl-palmitate absorp-
tion and in improving clinical outcome [112].
In animal models, EFAD does not affect the lipolytic
phase: there is no difference between EFAD and control
rodents in the lipolytic step [113,114]. Furthermore, ani-
mal models suggest that EFAD is likely to be of minor
importance in exocrine pancreas function in CF
[113,115]. Furthermore, EFAD does not seem to induce
any significant changes in the structure and composition
of pancreas [116]. Overall, these studies show that struc-
tured TG can effectively supply functional FAs distributed
throughout the glycerol skeleton. In particular, structured
TG with EFAs at the Sn-2 position and medium chain FAs
at the Sn-1 and Sn-2 positions of the glycerol molecule
can be used for distinct nutritional and clinical purposes
in CF. Although, it is obvious that structured TG are far
superior to conventional oils, it is quite difficult to appre-
ciate their influence on lipolysis in CF patients with EFAD
in view of the paucity of information available in the lit-
erature. Probably, the difficulty originates from the enor-
mous cost of producing highly purified structured TG.
III.1.3. Phospholipase A2 (PLA2) and Cholesterol Esterase 
(CET)
The phospholipid-hydrolyzing enzymes include phos-
pholipase A1 (PLA1), PLA2 and CET [117]. PLA1 and PLA2
are secreted in their zymogen form and activated by
trypsin on entering the duodenum [118]. PLA2 preferen-
tially hydrolyzes FA in phosphatidylcholine (PC), the
most abundant dietary PL, at position 2 to produce more
hydrosoluble components (FA and 2-lyso-PC). CET
hydrolyzes CE, retinyl ester and lyso-PC in the small
bowel [117], but it is 100 times less effective than pancre-
atic lipase in the TG digestion process.
In CF patients, PLA1 and PLA2 activity is correlated with
the pancreatic function [119]. It is of particular interest to
note that, despite the total absence of PLA2, around 30%
of PLs are hydrolyzed [120]. The decreased activity of PL
hydrolyzing enzymes may interact with lipid absorption
in several ways. First, since PLs are amphipathic mole-
cules, they adsorb to the surface of lipid droplets, prevent-
ing contact between the lipase-colipase complex and thePage 5 of 18
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lyso-PL from lipid droplets, which are relatively hydrosol-
uble molecules, and will thus facilitate the interaction
between TG and pancreatic lipase. Secondly, unhydro-
lyzed PLs impair the absorption of cholesterol and FAs
[121,122]. Finally, they impair bile acid absorption
through their receptors in the terminal ileum, which
increases bile acid losses in the stool.
In CF children, CET activity is dramatically decreased
[123] and parallels pancreatic lipase activity. The reduc-
tion in BAs, which are essential cofactors for optimal este-
rase activity, results in a failure to solubilize and thus
absorb cholesterol and their esters.
In the enterocyte, lyso-PC is an essential source of PLs for
LP formation [124], the transport of TGs from the entero-
cyte into the blood [125] and the PL turnover induced by
exocytosis [126]. These phenomena may be impaired by
phospholipase or CET defects.
No data are provided about the impact of EFAD on PLA1,
PLA2 and CET activity. However, AA and DHA decrease
the secretion of bile-salt dependent lipase, but without
directly impairing the biosynthesis of this enzyme. AA
alters the transport of the enzyme toward the cytosol,
leading to the retention of bile-salt dependent lipase in
microsomes [127]. It is likely that much attention must be
paid to phospholipases and CET in CF in view of their role
in fat absorption. Future studies should be designed to test
whether their supplementation may increase lipolysis effi-
ciency and alleviate EFAD in CF.
III.1.4. Intraluminal pH
Duodenum pH results from an interaction among food
buffering, gastric acid production and pancreatic bicarbo-
nate secretion. In humans, physiological pH is 2–4 in the
stomach and it varies from 6–7 in the upper duodenum,
but rarely dips below 5.
In CF patients, pancreatic, intestinal and biliary HCO3-
secretion is decreased to below 10% of the normal values
[128]. Consequently, a low pH is observed in the intesti-
nal lumen of the duodenum and even during postpran-
dial time. Besides, basal and postprandial pH levels in the
stomach are similar in CF patients and normal subjects
[91,96]. In CFTR(-/-) mouse intestine, HCO3- secretion is
impaired too [129,130]. The acidic upper small intestine
in CF may contribute to fat malabsorption given: 1) the
inactivation of trypsin, which induces an impairment of
active enzyme molecules from their zymogen form (pan-
creatic lipase, PLA2); 2) the inactivation of pancreatic
lipase [131]; 3) BA precipitation, decreasing the BA pool
and diminishing its availability to form micelles; and 4)
early protonation, which impairs the micellar dispersion
of lipolytic products [132]. The ability of acid suppressant
therapy (cimetidine, ranitidine or proton pump inhibi-
tors) to improve fat absorption is controversial. Recently,
a metanalysis of randomized trials involving agents that
reduce gastric acidity has been carried out and it showed
that treatment failed to improve nutritional status and
had little impact on fat absorption [133]. Differences
between studies could be due to the small number of sub-
jects, differences in dietary intake and the degree of pan-
creatic insufficiency, the important physiologic range in
fat intestinal absorption and variability in intestinal drug
absorption or interindividual variation in medication bio-
availability, pH measurement and fat absorption evalua-
tion.
III.2. Micellar Phase and Biliary Abnormalities
BAs are amphipathic molecules synthesized by the liver.
They enhance the solubility of lipolytic products in the
aqueous intestinal phase [134,135]. In fact, micellar solu-
bilization increases the aqueous concentration of MG and
FA 100 to 1000 times. The importance of this phase is
underscored by a 30% reduction in dietary lipid absorp-
tion in patients with biliary atresia [136]. Similarly, rats
with biliary drainage displayed reduced linoleic acid
absorption [137].
III.2.1. BA Excretion
Outside the critical micellar concentration range, the
amount of lipid solubilized is significantly reduced. Con-
sequently, steatorrhea appears [138] and FA absorption
decreases [139]. This situation is found in CF patients
where total bile salt secretion is impaired [140]. About
36% of CF children showed reduced BA secretion into the
duodenum [141]. Despite this low BA secretion, impaired
water secretion leads to high concentrations of bile salts in
hepatobiliary secretions [142], which may contribute to
the cholelithiasis reported in CF patients [94,143].
EFAs regulate BA excretion: PUFAs are reported to induce
the excretion of BA in rats [144] and humans [145], but
this effect depends on the EFA family, since n-3 FA
increases bile flow more than n-6 FA [146]. The EFAD
effect on bile flow and BA secretion varies among animal
species: decreasing in rats [147,148], having no effect in
mice [114] and increasing in hamsters [114]. In humans,
the impact of EFAD on BA secretion and composition
remains unclear. However, prostaglandins, which are AA
metabolites, alter hepatic bile flow [149] indicating that
disturbances of AA status may affect choleretic response in
CF patients.
III.2.2. BA Composition
The nature of BAs influences their ability to solubilize lip-
ids. Cholesterol absorption by enterocytes is greater with
cholyl-taurine than with chenodeoxycholyl-taurine [150-Page 6 of 18
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than glycine-conjugated BAs at solubilizing lipids. The
effect of EFA on BA composition variation and fat absorp-
tion remains enigmatic in humans, since there are no
available data.
In CF, oral taurine load appears to be normal, but exces-
sive fecal loss [153] increases the ratio of glycine/taurine-
conjugated BA [94,140,141]. Oral taurine supplementa-
tion in CF children is effective in decreasing the glycine/
taurine ratio in duodenal fluid [153], but its ability to
improve fat malabsorption is controversial [154-157].
Apparently, taurine supplementation improves BA malab-
sorption, mainly in patients with a high degree of steator-
rhea [158-160].
Studies on animals show that EFAD leads to impaired bil-
iary excretion of taurocholate [161] and to reduced EFA
content (linoleic and arachidonic acid) in biliary PC that
is essential for micelle formation [162]. However, BA and
bile lipid composition vary across species. In rats and
hamsters with EFAD, bile composition is markedly
impaired [147,161]. On the other hand, BA composition
appears to be similar in EFA-deficient and EFA-sufficient
mice [114].
The relationship between BA and EFA was investigated in
CF-EFAD children and it showed that ursodeoxycholic
acid supplementation improves the hepatic metabolism
of EFA. After 1 year, ursodeoxycholic acid supplementa-
tion led to an improvement of EFA status (reduction of
triene/tetraene FA ratio) [163].
III.2.3. BA Malabsorption
BAs are recycled through the enterohepatic cycle with
remarkable efficiency (95% reabsorbed) [164,165]. The
enterohepatic cycle is often interrupted in CF because of
excessive fecal losses of BA, [95,166-170], which diminish
the BA pool [171,172]. Excessive BA losses may be attrib-
uted to: 1) BA irreversibly bound to unhydrolyzed TG and
PL within the intestinal lumen [173] ; 2) BA precipitation
due to acidic pH in the duodenum [174]; and 3) intestinal
bacterial overgrowth, which is present in 40% of CF
patients and results in BA deconjugation and dehydrata-
tion [175]. BA loss may also result from a primary cell
defect in the active absorption of BA in the ileum. In vitro
studies using brush border membrane vesicles from CF
patients have shown that total ileal BA uptake is dimin-
ished [176,177]. Surprisingly, a study of Ileal Biliary Acid
Transporter (IBAT) in CFTR knock-out mice shows a BA
uptake rate four-fold that of wild-type mice [178]. The
increase in IBAT protein and BA uptake can be interpreted
as an up-regulation in response to a low BA rate. This
result should lead to a renewed interest in intraluminal
events, especially for the implication of the thick mucus
barrier in CF pathophysiology.
III.3. Gastric and Intestinal Transit Time
Fat digestion begins in the stomach with the action of acid
lipase. Following hydrolysis by gastric lipase, medium-
chain FAs are partly absorbed by the stomach [179]. Thus,
the stomach plays an essential role in fat digestion, espe-
cially in pancreatic insufficiency [147].
In CF patients with pancreatic insufficiency, altered motil-
ity with an increase in gastric emptying [180] and small
bowel transit time has been described [181-184]. It has
been reported that slow gastric emptying reduces the suc-
cess of pancreatic enzyme replacement therapy in improv-
ing TG hydrolysis, which could explain in part the
variation in pancreatic enzyme replacement therapy effi-
ciency [180,185]. However, other studies have shown that
gastric emptying time is similar in both CF patients and
healthy controls [90,182].
In EFAD rats, AA and linoleic acid are emptied from the
stomach at similar rates and these rates do not differ from
controls [186]. However, EFA-deficient mice show that
the motility of epithelial cells is increased in the jejunum
[187].
III.4. Intestinal Mucosa Trophicity
III.4.1. Quantitative and Qualitative Mucosal Abnormalities
In the majority of CF patients, histological brush border
studies reveal normal morphology [188]. However, in
some cases, abnormalities are reported, such as ileal
hypertrophy [189] or partial villous atrophy in the small
intestine [190,191]. This atrophic mucosa, which also
occurs in knock-out mice [189], may result from acidic
aggression by unbuffered stomach chyme, chronic inflam-
mation or denutrition. Furthermore, a thick mucinous
layer covering the brush border and large areas of the
microvilli is revealed by electron microscopic examina-
tion of biopsies from CF patients [188], which may con-
tribute to malabsorption in CF patients. The viscosity of
the intact CF glycoprotein is almost two-fold that of nor-
mal glycoprotein [192]. Elevated viscosity may be caused
by defective chloride transport, mucin hyperglycosylation
or a high level of disulfide-linked peptides [193,194].
Obviously, the highly acidic properties of surface compo-
nents related to oversulfatation could modify the micro
acidic climate on the intestinal epithelium surface and
influence interaction between micelles and enterocytes,
impairing the protonation of FAs.
In EFAD, histological and biochemical alterations of the
intestinal mucosa are described [195]. In rats and mice
with EFAD, the height of villi is decreased leading to a
diminished absorption area. Cellular differentiation wasPage 7 of 18
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EFA in the formation of new tissues, such as the mainte-
nance of tissue and cell structure [197]. Furthermore, the
abnormal structure of mitochondria and microvilli is cor-
related to decreased fat absorption [196]. It seems difficult
to reconcile jejunal hypertrophy in CF patients and micro-
villi in EFAD animals. However, EFAD seems to induce
histological abnormalities in the CFTR function. In CFTR
knock-out mice, jejunal hypertrophy is corrected with an
oral administration of high doses of DHA [198], which
are associated with an inhibitory proliferative cell effect
[199]. Then, more than in typical EFAD, an abnormal EFA
imbalance could lead to hypertrophic villosities in CF
patients. Hypertrophy is only localized in the jejunal por-
tion. Accordingly, the FA composition of jejunum
mucosa, the main segment for optimal lipid absorption,
is markedly different from ileal and colonic mucosa [195].
Furthermore, it is interesting to note that dietary influ-
ences are tissue specific, since serum or red blood cell
membranes do not reflect local changes in any of the dif-
ferent intestinal segments [195]. At present, no studies
have correlated intestinal morphology in CF patients with
their EFAD status.
III.4.2. Intestinal Permeability
Recently, studies have suggested that pathological modifi-
cations in EFAD may be the consequence of cell adhesion
disorders [200].
In CF patients, the dual sugar permeability test [201] dem-
onstrates that the paracellular pathway is more permeable
to large molecules, while the passive transcellular uptake
of small molecules is normal [182]. Intestinal permeabil-
ity in CF is related to patient genotype: patients
homozygous or heterozygous for ∆F508 mutation exhibit
significantly increased intestinal permeability compared
with patients with unidentified genotypes or controls
[202]. Moreover, abnormalities in the tight junction, an
essential structure for the control of intestinal permeabil-
ity, have been reported in the intestinal epithelium of
fetuses with CF [203].
EFAs are able to modify cells ultrastructurally and to alter
intestinal permeability. In the culture of enterocytes from
EFA-deficient CF, the lateral surfaces between cells are
fairly straight, a consequence of the absence of complex
interdigitations that play an essential intercellular cohe-
sive role [196]. Moreover, a reduction in the number of
desmosomes has been reported in the intestinal tract of
EFAD rats [59,204]. Studies in endothelial cells suggest a
possible mechanism of EFA-modulating cell adhesion.
However, this EFA function has to be demonstrated in
intestinal cells. In endothelial cells, some PUFAs such as γ-
linolenic acid or EPA increase transepithelial electrical
resistance and reduce paracellular permeability. Studies
involving CF patients are definitely needed to assay intes-
tinal cell adhesion molecules and their relation to FA sta-
tus.
IV. Enterocyte Phase Abnormalities
IV.1. Enterocyte Lipid Uptake
IV.1.1. Physiology
EFAs may be absorbed by enterocytes, mostly in the form
of EFA and MG. Until recently, it was assumed that these
lipids diffused passively through the enterocyte brush bor-
der membrane [205]. Indeed, earlier studies reported that
the uptake of FAs occurred at 0°C, implying that the proc-
ess is strictly passive. In particular, the intestinal absorp-
tion mechanism of linoleate was noted to depend on its
intraluminal concentration, showing a passive diffusion
at high concentrations. However, a transporter was
required at weaker concentrations [206]. Accordingly, the
absorption of FFA was found to be a saturable phenome-
non that can be inhibited through competition with long-
chain PUFA [207]. These observations suggest that FA
uptake is a concentration-dependent dual transport mech-
anism involving both passive diffusion and a carrier-
dependent process. Recently, several membrane transport
systems have been identified and they seem to be involved
in the enterocyte absorption of lipids: membrane FA bind-
ing protein (FABPm), capable of facilitating transmem-
brane passage mainly of FAs, but other lipids as well [208-
210]; FA translocase/cluster determinant 36 (FAT/CD36)
implicated in long-chain FA transport. [211-213]; scaven-
ger Receptor class B type I (SR-BI) that plays a role espe-
cially in cholesterol movement (absorption and/or efflux)
at the enterocyte level [214]; ATP Binding Cassette trans-
porter family that provides several cholesterol carriers:
ABCG5 and ABCG8 cooperate to limit sterol intestinal
absorption, rather facilitating cholesterol efflux toward
the intestinal lumen and their mutations predispose to
sitostrolemia [215,216]; and ABCA1 expressed in the
enterocyte, which could partially control cholesterol
efflux toward the intestinal lumen [217], although its
exact role in the brush border membrane remains contro-
versial [218,219]. Recently, a new protein called Nieman
Pick C1-Like1 was identified in the small intestine. It
seems closely involved in intestinal cholesterol absorp-
tion, a pathway sensitive to sterol absorption inhibitors
such as ezetimibe [220,221].
IV.1.2. CFTR and Lipid Transporters
No study to our knowledge has investigated the interac-
tion that may exist between the CFTR and these lipid
transporters. Yet, the CFTR is known to modulate the
activity of other carriers as well as certain ionic channels,
for instance [37,222]. The CFTR regulation of other intes-
tinal ionic transporters is effectively diminished in CF
patients [223]. Furthermore, a microarray study on pul-
monary tissue from knock-out CFTR mice shows thatPage 8 of 18
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glutamate, hormones or neurotransmitters have their
expression influenced by CFTR [224]. The completion of
the same type of study on intestinal tissue would likely
offer interesting tracks to target lipid transport proteins
capable of being influenced by the CFTR. The large diver-
sity of transporters interacting with the CFTR could lead to
impairment in enterocyte lipid uptake and trafficking in
CF, which would represent another cause for nutrient
malabsorption.
The existence of anomalies in the enterocyte uptake to
EFA is controversial. In effect, EFA intestinal absorption in
patients does not always appear to be impaired. Some
studies report that the rate of linoleic acid absorption is
normal when pancreatic enzyme supplementation is
given at sufficient doses [225]. Apparently, even the pres-
ence of steatorrhea was not accompanied by diminished
EFA absorption [186] and no correlation has been estab-
lished between steatorrhea and EFAD in preadolescents
with CF [226]. On the other hand, a recent study has
shown that patients undergoing pancreatic enzyme treat-
ment display a reduction in the intestinal uptake of long-
chain FAs [9]. The differences between these studies may
indicate either that the intestinal malabsorption does not
in itself explain the EFA deficit or that the severity of CFTR
mutation could influence the enterocyte absorption of
lipids. Unfortunately, genotyping analysis has not been
carried out in most of these investigations. Future devel-
opments will get to the bottom of these major unsolved
questions by tracing the defects in enterocyte lipid uptake,
the status of lipid transporters, the relationship with CFTR
in CF patients and fat malabsorption.
IV.1.3. EFAD and Lipid Transporters
Early studies on EFAD did not notice an anomaly in the
enterocyte transport of EFA [186,196,227]. However,
these data have not been confirmed. The studies are some-
what outdated and the sensitivity of the techniques used
may be called into question. Furthermore, several ele-
ments suggest that EFAD may be implicated, at least to
some extent, in lipid intestinal malabsorption. Indeed,
EFAD can affect the lipid composition of the enterocyte
membrane and modify its fluidity, which may directly dis-
turb the functioning of the transporters that can be found
there. Moreover, some transporters like the SR-BI or CD36
could act as transporters, not directly, but by creating a
special micro-environment in the neighbouring mem-
brane lipids. This local change favors the transfer of their
ligands [228]. In this model, it appears very likely that a
modification of the physiochemical properties of the
membrane, as is the case in EFAD, may impact on the
transporter lipid transfer abilities. EFAD could also influ-
ence these lipid transporters more directly. In effect, most
of these transporters are regulated by long-chain FAs: the
expression of the FABP and CD36 genes is increased by
long-chain FAs [229]; the SR-BI protein is also regulated
according to the type of long-chain FAs (unpublished per-
sonal data); and finally, the polyunsaturated FAs trigger a
decrease in the ABCA1 protein, thereby reducing the baso-
lateral efflux of cholesterol in human Caco-2 cells [230].
This regulation could be drilled through a reduction in
ABCA1 expression [231] or an increase in the degradation
of the protein [232].
FAs can also act directly on the level of expression of the
CFTR protein. In this way, a short-chain FA, the butyrate,
increases CFTR expression significantly in animal epithe-
lium cell cultures [233]. It is interesting to note that this
same FA modulates lipid synthesis, the biogenesis of apol-
ipoproteins (apos) and the assembly of LP in the entero-
cyte [234]. To our knowledge, there are no similar studies
with long-chain FAs or EFAs. The potential role for the
CFTR in all the enterocyte lipid synthesis steps underlines
the need for new investigations, which may lead to new
therapeutic strategies.
IV.2. Enterocyte Lipid Trafficking
IV.2.1. Physiology
After crossing the brush border membrane, the lipids
must be processed by cytosolic proteins for their intracel-
lular trafficking toward various compartments, including
the endoplasmic reticulum (ER), where their reesterifica-
tion may take place. However, the precise mechanisms
behind this transport remain unclear. Certain transport
proteins have been identified, but their roles often remain
hypothetical: the Sterol Carrier Protein (SCP-2) and two
cytosolic FABP capable of linking FA in particular, but also
PL. According to our unpublished and preliminary data,
intestinal-FABP (I-FABP), which is restricted to the intes-
tine, could direct the FAs to membranes for lipid cycling
or to a degradation pathway (peroxisome or mitochon-
dria), whereas the liver-FABP (L-FABP), also found in the
liver, could guide them to the ER to be assembled into LP.
I-FABP and L-FABP bind differently according to lipid
class, but both with a greater affinity for unsaturated FAs
than saturated FAs.
IV.2.2. CFTR and Enterocyte Lipid Trafficking
No study has examined the interactions that can exist
between the various proteins of the cytoplasmic transport
of lipids and the CFTR. However, it has been clearly dem-
onstrated that anomalies in CF exist in the intracellular
movement of the CFTR itself. Various physiochemical
conditions, such as low temperatures [233] or chemical
agents [235], are able to increase the stability of the
mutated CFTR protein and avoid its abnormal retention
in the ER [236,237]. The latter would, in part, be attribut-
able to a defective interaction between the CFTR and cer-
tain PLs that play the role of lipid chaperones. Obviously,Page 9 of 18
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ability to bind preferentially with phosphatidylserine
rather than with PC. The replacement of PC with non
charged analogues in mutated cell cultures increases CFTR
expression and the quantity of its mature form. Therefore,
certain PLs through their lipid chaperone function seem
important for the intracellular trafficking of the CFTR
[238]. Moreover, the invalidation of the CFTR initiates
changes in gene expression as well as protein degradation
via ubiquitin-dependent proteasome, which may modify
several transport proteins [224]. Overall, these studies
support the concept that CFTR is modulated by PLs and
indicate potential relationships between CFTR and other
local transporters. Unfortunately, it remains unknown
how EFAs contained in PLs directly alter the activity of
CFTR and whether a "partnership" exists between CFTR
and intracellular lipid transporters in the enterocyte.
Forthcoming investigations will highlight new links
between the CFTR, EFAs and cellular processes, which
may identify important factors that play a role in networks
of lipid signalling and transport.
IV.2.3. EFA and Enterocyte Lipid Trafficking
The assembly of microtubules is critical for intracellular
trafficking and chylomicron transport [239,240]. Early
reports had indicated that the administration of microtu-
bule inhibitors led to a decrease in the conveyance of radi-
oactive lipids in rat enterocytes [241]. Certain EFAs, such
as γ-linoleic acid or AA, regulate the microtubule polym-
erization [242,243]. Thus, EFAD could hinder intraente-
rocyte trafficking through an alteration of microtubule
polymerization, synthesis or function.
IV.3. Lipid Esterification and Lipoprotein Synthesis
IV.3.1. Physiology
The products of lipolysis once absorbed and transported
to the ER are resesterified to form TG, PL and CE through
specific enzymatic pathways. This reesterification involves
several enzymes monoacylglycerol acyltransferase
(MGAT), diacylglycerol acyltransferase (DGAT), glycero-
phosphate acyltransferase, phosphatidate phosphodieste-
rase, lyso-PC acyltransferase, CE and acyl-coenzyme
A:cholesterol acyltransferase (ACAT). After their synthesis,
hydrophobic lipids must be associated with proteins or
apolipoproteins, in order to allow their solubilization in
the blood circulation, thereby forming complexes known
as LP. The intestine is capable of secreting most lipopro-
tein classes (chylomicrons, VLDL, HDL), but chylomi-
crons represent the specific and most abundant class in
the enterocyte.
Note that apo B is a component that is essential for LP
assembly and secretion by the intestine. It exists in two
forms: apo B-100, present particularly in the liver, but to
a limited extent in the intestine, and apo B-48, which is
specific to the enterocyte that results from the posttran-
scriptional modification of the apo B-100 mRNA, or edit-
ing, involving an enzymatic complex called APOBEC-I
(apo B mRNA-editing catalytic subunit-1) [244]. Other
apos are produced in the enterocyte, mainly apo A-I and
apo A-IV that is exclusively of intestinal origin in humans
[245]. During its synthesis in the ER, apo B must undergo
lipidation that protects it from degradation by the protea-
some [246]. Lipid transfer from the endoplasmic reticu-
lum to apo B requires microsomal triglyceride transfer
protein (MTP) intervention. This step is crucial for chy-
lomicron assembly as noted in abetalipoproteinemia, an
illness brought on by the mutation of the MTP gene,
where there is defective lipoprotein secretion [247].
Pre-chylomicrons are exported to the Golgi apparatus
where they undergo their final maturation (glycosylation
of the apos, modification of certain PLs, etc.) before being
secreted through the basolateral membrane into the lym-
phatic milieu. It is important to note the role of cargo pro-
teins in the secretion step, which has been highlighted in
chylomicron retention disease: the mutation of the Sar-1
GTPase protein prevents the secretion of chylomicrons
through the dependent COPII vesicles [248]. TG transfer
from the ER to the Golgi apparatus seems to be a limiting
step in fat absorption [249]. After being secreted into the
lymphatic capillaries, intestinal LPs are discharged into
the systemic blood circulation through the thoracic canal.
IV.3.2. Role of the CFTR in the Intracellular Phase
In CF patients, lipid composition, concentration and size
are irregular [250]. At present, the role played by CFTR
anomalies is unknown. To our knowledge, no study has
focused on the possible interactions of the CFTR with the
implicated enzymes in lipid reesterification, apo B biosyn-
thesis, MTP activity or the relationship with Sar-1 GTPase
protein expression.
It is during this LP secretion step that interactions with the
CFTR may be the most likely. In fact, CFTR mutations alter
the secretion not only of electrolytes, but also of sub-
stances as different as BAs by the hepatocyte [172], γ-light
chain antibodies by lymphocytes [251], INFγ by mono-
cytes [252] or neurotransmitters by pulmonary neuroen-
docrine cells [253]. Since the enterocyte represents a key
cell in the physiopathology of CF and given the numerous
lipid aberrations observed in this disease, it appears essen-
tial to study the secretion abilities of lipids by epithelial
cells instead of focusing only on the digestive mechanism
in CF as is presently the case. For example, the recent anal-
ysis of RNA, influenced by CFTR knock-out, identified a
number of proteins involved in LP metabolism, including
proteasome 26S [224]. The latter subunit is the major pro-
teolytic component of the ubiquitin-dependent proteas-
ome. As mentioned before, the ER-localized ubiquitin-Page 10 of 18
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lular degradation of apo B. Its alteration in the absence of
CFTR [224] indicates potential relationships between
CFTR and the apo B recovery/degradation pathway,
thereby determining LP assembly and secretion. Further-
more, there is increasing evidence that CFTR regulates
endosomal fusion and vesicular trafficking [254], indicat-
ing potential relationships between the CFTR and ADP-
ribosylation factor [254], which has a central role in VLDL
assembly [255]. Finally, the Sar-1/COPII complex is nec-
essary when apo B-100 exits the hepatic ER [256] and apo
B-48 containing chylomicrons are exported from the ente-
rocyte [248]. However, the Sar-1/COPII complex is also
implicated in the exiting of CFTR from the ER [257] for its
entry into the proteasome degradation pathway [258].
Overall, these observations demonstrate the existence of
possible interactions among apo B elaboration, chylomi-
cron packaging and CFTR function. Hence, CFTR muta-
tions may significantly affect lipid transport and
obviously studies are needed to clarify this relationship.
IV.3.3. Possible Implications of EFAs in Intracellular Lipid Transport
It is important to underline that the anomalies in the
reported LP during CF are most marked in patients with
EFAD [250]. These defects may either be the direct conse-
quence of EFAD on LP synthesis or may only reflect an
association between the type of CFTR mutation and lipid
metabolism. A phenotypic classification of LP profiles
according to genotype would allow us to elucidate this
question. In fact, EFAD could cause interference at several
levels within the process of LP synthesis and secretion.
TG reesterification rates are diminished in rats during
EFAD [259,260]. Lipid membrane modifications, notably
long-chain FAs, are known to change the functioning of
reesterification key enzymes such as MGAT [261]. Simi-
larly, intake rich in (n-3) FA lowers the ratio (n-6)/(n-3)
and leads to an activation of DGAT and ACAT [262].
Therefore, an unbalancing of the EFA status could affect
the lipid reesterification step.
Biosynthesis through the enterocytes of several apos, such
as apo B or apo A-IV, is regulated in a specific way by cer-
tain EFAs [263-265]. Experimental studies confirm inves-
tigations carried out on humans [266]. Thus, EFAD is
possibly deleterious for the synthesis of the main intesti-
nal LP. Accordingly, enterocyte secretion of synthesized
lipids is impaired during EFAD in mice and rats, which
translates into an accumulation of large lipid droplets in
the intercellular space [196]. Notably, in EFAD, the bal-
ance between the various EFAs rather than directly the
absence of EFAs could impair the exocytosis mechanism.
In effect, in enterocyte cultures, certain EFAs, such as EPA,
decrease TG esterification and PL transfer from the ER to
the Golgi and the mechanisms responsible for these proc-
esses have not yet been specified [267]. Similarly, EFAD
may affect microtubules [242-268], as we previously men-
tioned, which could impact on the assembly and secretion
of chylomicrons [239,240,242].
V. Conclusion
It is well established that defective digestive processes in
CF patients are secondary to pancreatic insufficiency.
However, it is difficult to reconcile the failure of appropri-
ate pancreatic enzyme replacement therapy with the per-
sistent fat malabsorption. Since mutations in CFTR result
in impaired intracellular pH organelle, glycosylation and
sialylation in mammalian cells, it is possible that distur-
bances in intestinal CF lipid transport may also be associ-
ated with cause-related changes in the second step of fat
absorption, i.e. the intracellular phase leading to lipolytic
product uptake and esterification, apolipoprotein synthe-
sis and processing, and nascent lipoprotein assembly and
secretion following the fusion of Golgi vesicles with the
basolateral plasma membrane. This hypothesis is rein-
forced by the findings that CFTR dysfunction alters further
intracellular pathways, crucial for lipoprotein packaging
and delivery, such as ubiquitin-proteasome complexes,
endosomal fusion and vesicular trafficking, as well as
Sar1/COP II and ADP-ribosylation factor 1/COP I sys-
tems. Additionally, in keeping with substantial growing
evidence from the available literature, it is reasonable to
put forward that EFAD contributes to CF malabsorption
by interfering with intra-enterocyte lipid transport. If pre-
vious studies had entirely attributed EFAD to diminished
EFA intake and malabsorption, it is likely today that a
mutated CFTR may also decrease the incorporation of
EFAs in PL [42], increases the release of AA [49], lowers
the concentrations of linoleic acid and DHA, and disrupts
EFA metabolism [42,50]. An interrelation between CFTR
and EFAs is demonstrated when the chloride channels are
blocked chemically [41]. Nevertheless, the exact relation-
ship between CFTR and EFAs remains unclear and studies
in this fundamental direction would shed considerable
light on our understanding of the mechanisms responsi-
ble for EFAD in CF. This aspect is particularly important
given the suggestions that EFAD is related to a basic defect
in FA metabolism. It seems imperative that rigorous and
long-term studies be conducted on EFA supplementation
to normalize EFA status in CF patients, otherwise EFAD
would continue to affect intestinal lipid transport and to
simultaneously exacerbate the poor clinical course of the
CF patients.
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